A new needle-free option for treating severe allergic reactions has been approved in Canada, offering a potentially significant shift in how patients manage life-threatening emergencies.
Health Canada has authorized the use of a nasal spray known as “neffy,” which delivers epinephrine without the need for an injection.
The treatment has been approved for adults and children who weigh at least 30 kilograms and could be available as early as this summer, officials have announced.
The new option provides an alternative to traditional epinephrine auto-injectors, such as the EpiPen, which have long been the primary emergency treatment for anaphylaxis.
Medical experts say the nasal spray format could help address barriers that prevent some individuals from carrying or using injectable devices.
Anaphylaxis can present in a variety of ways, including difficulty breathing, swelling, low blood pressure and skin reactions.
It is commonly triggered by food allergies, insect stings or medications and requires immediate treatment.
Experts also point out that the new nasal spray may be easier to carry and store, as it is more temperature-stable than traditional injectors.
However, they emphasize that having multiple treatment options available is key, particularly in cases where supply shortages or backorders affect access to existing medications.
Health professionals say the introduction of neffy adds an important new tool for patients and families managing severe allergies, as the number of people affected continues to rise.
